| Juvenile Rheumatoid Arthritis (JRA) |
1 |
1 |
| Child |
0 |
0.99 |
| Arthritis |
0 |
0.47 |
| Psoriatic Arthritis |
0 |
0.38 |
| Rheumatoid Arthritis |
0 |
0.35 |
| Uveitis |
0 |
0.34 |
| Remission |
0 |
0.25 |
| Disease-Modifying Antirheumatic Drugs |
0 |
0.98 |
| Hospital |
0 |
0.18 |
| Revenue and Practice Management |
0 |
0.16 |
| Genetics |
0 |
0.14 |
| Genomic Medicine |
0 |
0.14 |
| Patient Safety |
0 |
0.13 |
| New York |
0 |
0.11 |
| Adolescent Medicine |
0 |
0.07 |
| Biologic Therapy |
0 |
0.07 |
| Rheumatic Disease |
0 |
0.07 |
| Adverse Effects |
0 |
0.04 |
| Antinuclear Antibody Positive |
0 |
0.04 |
| Blood |
0 |
0.04 |
| Disability |
0 |
0.04 |
| Europe |
0 |
0.04 |
| Fellowship |
0 |
0.04 |
| Patient History |
0 |
0.04 |
| Prognosis |
0 |
0.04 |
| Psoriasis |
0 |
0.04 |
| Refractory |
0 |
0.04 |
| Salary and Compensation |
0 |
0.04 |
| Transitional Care |
0 |
0.04 |